News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
Amgen (AMGN) And UCB Submit Biologics License Application For Romosozumab To The FDA 7/22/2016
Gilead (GILD)'s Odefsey Successful in Two Phase IIIb Studies 7/22/2016
Sunovion Pharmaceuticals Inc. Announces Results Of Phase III Long-Term Safety Study Showing SUN-101/Eflow® (Glycopyrrolate) Was Well-Tolerated In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 7/22/2016
Data For Merck & Co. (MRK)'s Investigational Once-Daily Formulation Of ISENTRESS (Raltegravir) Show That At Week 48, A Regimen Containing The Once-Daily Dosing Formulation 7/22/2016
Puma Biotech (PBYI) Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (Extenet Trial) 7/22/2016
Amgen (AMGN) And Allergan (AGN) Biosimilar Found as Effective as Genentech (RHHBY)'s Herceptin 7/21/2016
Zafgen (ZFGN) Pinks Slips 34% of Workforce, Scraps Lead Obesity Drug After Deaths 7/21/2016
Actinium (ATNM.OB) Calls Investigator Meeting in Dallas 'Successful' 7/20/2016
Biohaven Commences Clinical Testing Of BHV-4157 7/20/2016
Genentech (RHHBY) Receives a Blow After Lymphoma Drug Flunks Phase III Test 7/19/2016
Evoke Pharma (EVOK) Stock Decimated After Late-Stage Trial Miss 7/19/2016
Alcobra (ADHD) Granted European Orphan Drug Designation For Metadoxine In Fragile X Syndrome 7/19/2016
CSL Behring To Present New Data For IDELVION And AFSTYLA At The World Federation of Hemophilia 2016 World Congress 7/19/2016
AstraZeneca PLC (AZN)'s TAGRISSO Met Primary Endpoint in Late-Stage Lung Cancer Trial 7/18/2016
Alizé Pharma To Present Results From AZP-531 Phase II Trial In Prader-Willi Syndrome At Two Upcoming Scientific Conferences 7/18/2016
ViiV Healthcare Release: ARIA Study Shows Superior Efficacy Of Triumeq For Treatment-Naïve Women Living With HIV 7/18/2016
BioLife Solutions, Inc. (BLFS.OB) Products Embedded In Cook MyoSite Phase 3 Cell Therapy Clinical Trial For Stress Urinary Incontinence 7/18/2016
Citius Pharma Completes Feasibility Study Of Investigator Sites For Mino-Lok Phase 3 Trials 7/18/2016
Biogen (BIIB) And Sobi To Showcase Long-Term Efficacy And Safety Data From Extended Half-Life Hemophilia Therapies At World Federation Of Hemophilia 2016 World Congress 7/18/2016
Ultragenyx (RARE) Rising on Phase III Acute Myeloid Leukemia Data 7/15/2016
European Regulator Calls XBiotech (XBIT)'s Phase III Cancer Data Unreliable 7/15/2016
BeyondSpring Pharmaceuticals Release: Investigator-Sponsored Plinabulin Combination Study For Metastatic Non-Small Cell Lung Cancer Granted FDA Clearance To Enroll Patients 7/14/2016
Pfizer (PFE) Shows Off Final Data from Two Late-Stage Dermatitis Studies 7/13/2016
Nuvo Pharmaceuticals Inc. Announces Pennsaid 2% Phase 3 Trial To Support Regulatory Approvals In The E.U., Canada And Australia 7/13/2016
Good News for Gilead (GILD) as Zydelig Passes Safety Review Test Despite Trial Deaths 7/12/2016
CytRx (CYTR) Craters After Aldoxorubicin Flops in Phase III Trial 7/12/2016
3 Nauseating Clinical Trial Flops of 2016 So Far 7/12/2016
Amgen (AMGN) To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab 7/12/2016
Cipher Pharma (DND.TO) Announces Ozenoxacin Accepted For Review By Health Canada 7/12/2016
Novo Nordisk A/S (NVO) To Present 28 Abstracts At The World Federation Of Hemophilia World Congress In Orlando 7/12/2016
ENGOT And Tesaro (TSRO) Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial 7/11/2016
Alexion (ALXN) Release: New Data From Phase III REGAIN Study Of Eculizumab (Soliris) In Patients With Refractory Generalized Myasthenia Gravis (Gmg) Presented At ICNMD Annual Congress 7/7/2016
AbbVie (ABBV) Shows Off Positive HUMIRA Phase III Data in Moderate to Severe Fingernail Psoriasis 7/7/2016
Janssen R&D And Johnson & Johnson (JNJ) To Provide Webcast Presentation On Phase 3 Data For DARZALEX (Daratumumab) And The Janssen Immuno-Oncology Strategy And Portfolio 7/7/2016
XBiotech (XBIT)'s Colorectal Cancer Drug Claims Fall Apart, Shares Plummet 7/6/2016
Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) Initiate Phase III Trial To Evaluate Avelumab As First-Line Treatment For Ovarian Cancer 7/6/2016
Merck & Co. (MRK) And Pfizer (PFE) Initiate Phase III Trial To Evaluate Avelumab As First-Line Treatment For Ovarian Cancer 7/6/2016
RiboMed Biotechnologies, Inc. And Tocagen Inc. Collaborate To Analyze Epigenetic Prognostic Markers, Including MGMT, In Recurrent Brain Tumors 7/6/2016
Bausch & Lomb And Nicox Announce The Publication Of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results In American Journal Of Ophthalmology 7/6/2016
FDA Grants Special Protocol Assessment to Advaxis (ADXS)’ Phase III Study Of AXAL In Patients With Cervical Cancer 7/6/2016
Ocular Therapeutix (OCUL) To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference 7/6/2016
This Year’s Top 10 Disappointing Clinical Trials—So Far! 7/6/2016
Teva (TEVA) And The Huntington Study Group Announce Publication Of Pivotal Phase III Data On Deutetrabenazine (SD-809) In Huntington Disease From First-HD Trial In JAMA 7/5/2016
CEL-SCI (CVM) Reports Monthly Patient Enrollment In June For Its Phase III Head And Neck Cancer Trial 7/5/2016
Mesoblast (MSB.AX) Plans to Reduce FY17 Cash Burn to Fund Clinical Operations and Phase III Heart Failure Trial 7/1/2016
Merck & Co. (MRK) Release: Results Of Pivotal TAILOR Study Confirm Addition Of Erbitux To FOLFOX Significantly Improves Outcomes In RAS Wild-Type Metastatic Colorectal Cancer 7/1/2016
Allergan (AGN) Receives Positive Opinion Through European Decentralised Procedure For BELKYRA (Deoxycholic Acid) For Patients With Submental Fullness 7/1/2016
Array BioPharma (ARRY) Submits Binimetinib New Drug Application To U.S. FDA 7/1/2016
Alnylam (ALNY) Reports New Results From Investigational RNAi Therapeutic Programs For Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN) And Cardiomyopathy (hATTR-CM) 7/1/2016
Galena Biopharma  (GALE) Craters and Discontinues Phase III Breast Cancer Vaccine NeuVax 6/30/2016
Infinity Pharma (INFI) Cuts Jobs by 58% as AbbVie (ABBV) Terminates Duvelisib Collaboration Deal 6/30/2016
Investors Gain Focus as Shire (SHPG) Stock Rises at Positive ADHD Drug News 6/30/2016
Merrimack (MACK) Release: NAPOLI-1 Data Demonstrates ONIVYDE Regimen Maintains Quality Of Life While Improving Overall Survival In Patients With Metastatic Pancreatic Cancer 6/30/2016
Xcovery Announces Initiation Of Phase 3 Trial Of X-396 In ALK+ Non-Small Cell Lung Cancer 6/30/2016
Biofrontera AG Initiates Phase III Trial Of Ameluz In Combination With Daylight-PDT 6/30/2016
Tesaro (TSRO)'s Phase III NOVA Trial of Niraparib Hits Primary Endpoint; NDA and MAA Planned for Q4 2016 6/29/2016
Esperion (ESPR) Falls on Lack of FDA Clarity for Cholesterol Drug 6/29/2016
Center Point Clinical Services Signs Partnership Agreement With ContraVir 6/29/2016
Anthera Provides Clinical Program Updates For Blisibimod And Sollpura 6/29/2016
Omeros (OMER) Announces Completion Of Patient Enrollment In Pediatric Trial Of OMIDRIA 6/29/2016
NeuroDerm (NDRM) Announces ND0612H Achieves Comparable Pharmacokinetics To DUODOPA In Head-To-Head Pilot PK Comparison Trial 6/29/2016
Celyad’s CHART-1 Phase III Shows No Significant Difference on Primary Endpoint 6/28/2016
BeyondSpring Pharmaceuticals's Global Phase III Non-Small Cell Lung Cancer Clinical Trial For Plinabulin Launches In China 6/28/2016
NewLink Genetics (NLNK) Stock Slides and Company Lays Off 87 After Failed Trial 6/28/2016
AcelRx (ACRX) Completes Patient Enrollment In Remaining Phase 3 Studies Of ARX-04 As A Potential Treatment Of Moderate-To-Severe Acute Pain 6/28/2016
Tobira’s Cenicriviroc Reduces Inflammation And Fibrosis In Animal Models Of Chronic Liver And Kidney Disease Including NASH 6/28/2016
Phase III Data Show Bayer (BAY)'s Stivarga (Regorafenib) Improved Overall Survival In Previously Treated Patients With Unresectable Liver Cancer 6/28/2016
Pfizer (PFE) Release: Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results 6/28/2016
Auris Medical AG (EARS) Completes Enrollment Of Phase 3 TACTT3 Trial With Keyzilen In Acute And Post-Acute Inner Ear Tinnitus 6/28/2016
Intensity Therapeutics, Inc. Raises $10 Million To Fund Clinical Supplies Manufacturing And Phase I/II Trials Of INT230-6 6/28/2016
VM BioPharma Announces First Patient Dosed In Phase 3 Study Of Gene Therapy Candidate, VM202, In Painful Diabetic Peripheral Neuropathy 6/27/2016
GW Pharma (GWPH)’s Epidiolex Meets Primary Endpoint in Phase III 6/27/2016
AnGes Terminates Phase III HGF Plasmid, Starts New Plan 6/27/2016
The Medicines Company (MDCO) Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE 6/27/2016
Axsome (AXSM) Added To Russell 3000 And Russell 2000 Indexes 6/27/2016
Teva (TEVA) Receives CHMP Positive Opinion For CINQAERO (Reslizumab) 6/24/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
BioCon (BIOCON.NS), Quark Pharmaceuticals Inc. Announce Initiation Of Pivotal Phase II/III Study Of QPI-1007 In Rare Eye Disease In India 6/23/2016
Innocoll (INNL) Announces The Completion Of Enrollment In Two Pivotal Phase III Clinical Trials Of COGENZIA For The Treatment Of Diabetic Foot Infections 6/23/2016
Incyte (INCY) Announces First Patient Treated In ECHO-301 Phase 3 Study 6/23/2016
Boston Biomedical Announces First Orphan Drug Designation For Napabucasin In Gastric/GEJ Cancer 6/23/2016
Merrimack (MACK) To Present New Analyses Of Phase 3 NAPOLI-1 Data At The ESMO 18th World Congress On Gastrointestinal Cancer 6/22/2016
Kite Pharma (KITE) and Juno (JUNO)'s R&D Strategy to Reshape Cancer Treatment 6/21/2016
Theravance Biopharma (TBPH) Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study Of The Closed Triple Announced By GlaxoSmithKline (GSK) And Innoviva 6/21/2016
Kiadis Pharma Appoints PCT As Its Contract Manufacturing Organization In The United States 6/21/2016
Ophthotech Corporation (OPHT) Completes Patient Recruitment In Phase 3 Trial Of Fovista Anti-PDGF Therapy In Combination With Eylea Or Avastin In Wet Age-Related Macular Degeneration 6/20/2016
GlaxoSmithKline (GSK)'s Lung Drug Passes Phase III Test 6/20/2016
Circassia (CIR.L) Stock Crashes as Allergy Drug Flunks Crucial Phase III Study 6/20/2016
Concordia Healthcare Announces PDT With Photofrin Data And Provides Corporate Update 6/20/2016
Allergan (AGN) Release: Data Presented at ASM Microbe Highlight In Vitro Antimicrobial Activity Of AVYCAZ (Ceftazidime And Avibactam) Against Several Species Of Enterobacteriaceae Pathogens And Pseudomonas Aeruginosa, Including Certain Resistant Strains 6/20/2016
ABIVAX Release: Analysis Of Ongoing ABX203 Phase IIb/III Trial In Chronic Hepatitis B Virus Infection Shows Good Safety, But Primary Endpoint Of Study Is Unlikely To Be Reached 6/20/2016
Navidea (NAVB) Announces Presentation Of Results Demonstrating Performance Of Lymphoseek In Breast Cancer At SNMMI 6/17/2016
Auris Medical AG (EARS) Initiates ASSENT Phase 3 Trial Of AM-111 For Treatment Of Sudden Deafness 6/17/2016
Stealth Biotherapeutics Reports Positive Elamipretide Data In First-Of-Its-Kind Primary Mitochondrial Myopathy Trial 6/17/2016
Medgenics, Inc. Announces Enrollment Of First Patient In Phase 2/3 Clinical Trial Of NFC-1 In Adolescents With mGluR Mutation Positive ADHD 6/17/2016
Aerie (AERI) Completes Enrollment Of Rocket 4 Phase III Clinical Trial Of Rhopressatm (Netarsudil Ophthalmic Solution) 0.02% 6/16/2016
Can-Fite BioPharma (CFBI) Reports New Data Showing Its Psoriasis Drug May Offer Efficacy Similar To Industry Leading Biologics Without Harmful Side Effects 6/16/2016
ContraVir Expands Patient Enrollment Criteria For Ongoing Phase III Clinical Study Of FV-100 For Treating Shingles 6/16/2016
Braeburn Pharma Release: Probuphine (buprenorphine) Implant Phase 3 Data Presented At CPDD Annual Scientific Meeting 6/16/2016
Pfizer (PFE) Head of R&D Talks Strategy on How Pharma Chooses Compounds to Bet A Billion Dollars On 6/16/2016
Merck & Co. (MRK) Soars as Keytruda Impresses in Late-Stage Lung Cancer Study 6/16/2016
Celator Pharma (CPXX) Announces Positive Results In Patients With FLT3 Mutation From The Phase 3 Trial In High-Risk Acute Myeloid Leukemia 6/15/2016
Jazz Pharma (JAZZ) Presents New Data From A Human Abuse Liability (HAL) Study For JZP-110, An Investigational Treatment For Excessive Sleepiness In Patients With Narcolepsy Or With Obstructive Sleep Apnea, At 30th Annual SLEEP Meeting 6/15/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Thymosin Beta 4 Effective In Treatment Of Heart Attack Patients 6/15/2016
Novo Nordisk A/S (NVO) Release: Faster-Acting Insulin Aspart Showed A Statistically Significant Reduction In Hba1c In Type 1 Diabetes And A Comparable Hba1c Reduction In Type 2 Diabetes Versus Novolog® (Insulin Aspart [rDNA Origin] Injection) 6/14/2016
IBSA Release: Prescription Chondroitin Sulphate Is As Efficacious As Celecoxib And Better Than Placebo In Knee Osteoarthritis 6/14/2016
Novo Nordisk Canada Inc. (NVO) Release: Faster-Acting Insulin Aspart Showed A Statistically Significant Reduction In Hba(1c) In Type 1 Diabetes And A Comparable HbA(1c) Reduction In Type 2 Diabetes Versus NovoRapid (Insulin Aspart) 6/14/2016
Amgen (AMGN) Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab 6/14/2016
Once Floated as Allergan (AGN) Target, Revance (RVNC)'s Stock Drops as Crow’s Feet Drug Fails Trial 6/14/2016
Sanofi (SNY)'s New Diabetes Combo Nails Late-Stage Goals 6/13/2016
SymBio Pharma Release: Initiation Of Phase III Clinical Trial On The Patient-Controlled Pain Management Drug "SyB P-1501" 6/13/2016
Catalyst Pharma (CPRX) Announces Agreement With FDA On Confirmatory Phase III Study Protocol For Firdapse In Lambert-Eaton Myasthenic Syndrome 6/13/2016
Dynavax (DVAX) Presents New Efficacy Data On Hepatitis B Vaccine, HEPLISAV-B, In Adults With Type 2 Diabetes At American Diabetes Association Scientific Sessions 6/13/2016
Marinus Pharma (MRNS)'s Stock Plummets as Seizure Drug Flunks Phase III Study 6/13/2016
Merck & Co. (MRK)’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint In Two Phase III Studies, Showing Non-Inferiority To Lantus 6/13/2016
REPEAT/Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016
Amgen (AMGN) Release: New Analyses From Pivotal Phase 3 Studies Show Kyprolis (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression 6/13/2016
Pfizer (PFE) Announces Final Results From Inotuzumab Ozogamicin Pivotal Phase III Study In Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia 6/13/2016
Seattle Genetics (SGEN) Highlights Vadastuximab Talirine (SGN-CD33A) Data In Acute Myeloid Leukemia (AML) At The 21st Congress Of European Hematology Association 6/13/2016
Merck & Co. (MRK) An Pfizer (PFE) Announce Two Pivotal Phase III Studies For Ertugliflozin, An Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions In Patients With Type 2 Diabetes 6/13/2016
AstraZeneca PLC (AZN) Presents Findings From Two Pooled Analyses At The 76th Scientific Sessions Of The American Diabetes Association Evaluating Dapagliflozin In Type 2 Diabetes Patients With Renal Impairment And In Combination With Potassium-Sparing Agents 6/13/2016
Janssen-Cilag International NV (JNJ)’s EPREX (Epoetin Alfa) Demonstrates Effectiveness As A Treatment For Anaemia In Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndromes 6/13/2016
Novo Nordisk A/S (NVO) Release: Tresiba (Insulin Degludec Injection U-100) Demonstrated Significantly Lower Rates Of Overall, Nocturnal And Severe Hypoglycaemia Vs Insulin Glargine U-100 6/13/2016
Janssen Pharmaceutical Presents New Data Showing Invokana (Canagliflozin) Is Associated With Greater Blood Glucose Control And Treatment Adherence Compared To Dpp-4 Inhibitors 6/13/2016
Intarcia Presents FREEDOM-2 Trial Results In Type 2 Diabetes Demonstrating Clinically Meaningful Superiority And Sustained Glucose Control And Weight Reduction For ITCA 650 Vs. Januvia: Oral Presentation At American Diabetes Association 76th Scientific Sessions 6/13/2016
Novo Nordisk A/S (NVO) Release: Semaglutide Demonstrated Superior Improvements In Glycaemic Control Vs Sitagliptin (SUSTAIN 2) And Exenatide ER (SUSTAIN 3) In Two Clinical Trials In Adults With Type 2 Diabetes 6/13/2016
Intarcia Release: New NHANES Analysis Shows No Improvement In Last Decade To Get More Diabetes Patients To Hba1c Goal; Separate Study Suggests Reduced Efficacy In Real-World Plays Large Role Due To Adherence Falling Far Short Of Clinical Trials 6/13/2016
Eli Lilly (LLY) Release: New Data Show Eli Lilly (LLY)'s Once-Weekly Trulicity (Dulaglutide) In Combination With Insulin Glargine Improves Glycemic Control In People With Type 2 Diabetes 6/13/2016
ProMetic Life Sci (PFSCF.PK)'s Plasminogen Granted Fast Track Designation By FDA 6/13/2016
Prothena (PRTA) Presents First Clinical Data for PRX003 for the Treatment of Inflammatory Diseases 6/10/2016
Incyte (INCY) Release: New Phase III Data Show Jakafi (Ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV) 6/10/2016
Janssen-Cilag International NV (JNJ) Release: Daratumumab Significantly Extended Progression-Free Survival In Combination With Lenalidomide And Dexamethasone In Patients With Multiple Myeloma 6/10/2016
Amgen (AMGN) Release: BLINCYTO (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia 6/10/2016
Janssen R&D Release: Daratumumab Significantly Extended Progression-Free Survival In Combination With Lenalidomide And Dexamethasone In Patients With Multiple Myeloma 6/10/2016
PTC Therapeutics (PTCT) Release: New Analyses From Phase 3 Study 009 Of Translarna (Ataluren) In Patients With Cystic Fibrosis Presented At 39th European Cystic Fibrosis Conference 6/10/2016
AVANIR (AVNR) To Present Data On ONZETRA Xsail At American Headache Society (AHS) 2016 Annual Scientific Meeting 6/10/2016
Vertex (VRTX) Announces Presentations Of Data For KALYDECO (Ivacaftor) And ORKAMBI® (Lumacaftor/Ivacaftor) At European Cystic Fibrosis Society (ECFS) Conference 6/10/2016
New Data Presented At The Annual European Congress Of Rheumatology (EULAR 2016) Demonstrate Safety And Efficacy Of Biogen (BIIB)’s Anti-TNF Biosimilars Portfolio 6/9/2016
ASCO2016: ProvectusAnnounces Poster Presentation On PV-10 At Annual Meeting Of American Society Of Clinical Oncology Now Available Online 6/9/2016
Eli Lilly (LLY) Release: Patient-Reported Outcomes Across Phase 3 Studies Of Baricitinib Demonstrate Statistically Significant Improvements In Physical Function And Quality Of Life Symptoms In Patients With Rheumatoid Arthritis (RA) 6/9/2016
Studies Demonstrate Eli Lilly (LLY)'s Taltz (Ixekizumab) Maintained Or Achieved High Levels Of Skin Clearance For Patients With Moderate-To-Severe Plaque Psoriasis Through 60 Weeks: Results Published In The New England Journal of Medicine 6/9/2016
Eli Lilly (LLY) Release: Baricitinib Significantly Reduces Joint Damage Progression In Rheumatoid Arthritis In Patients Who Do Not Respond To Conventional DMARDs 6/9/2016
AVANIR (AVNR) Release: NUEDEXTA Effective For Pseudobulbar Affect (PBA) In Patients With Alzheimer's Disease And Other Dementias, Stroke And Traumatic Brain Injury 6/9/2016
Bristol-Myers Squibb Canada (BMY) Release: Canada's Health Technology Assessment Agency Gives Positive Recommendation For OPDIVO To Treat Non-Small Cell Lung Cancer 6/9/2016
Mast Therapeutics (MSTX) Receives Notice Of Allowance Of Composition Of Matter Patent Application Covering Vepoloxamer 6/9/2016
GlaxoSmithKline (GSK), Johnson & Johnson (JNJ)'s Rheumatoid Arthritis Drug Meets Goals in Large Late-Stage Study 6/8/2016
New Janssen R&D Phase 3 Data In Patients With Moderately To Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression And Improved Signs And Symptoms Of Disease 6/8/2016
Trevena (TRVN) Announces First Patients Enrolled In The APOLLO-1 And APOLLO-2 Phase III Pivotal Efficacy Studies Of Oliceridine In Acute Pain 6/8/2016
Remedy Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CIRARA 6/8/2016
Samsung Bioepis Announces New Data On Three Anti-TNF--a Biosimilar Molecules At The Annual European Congress On Rheumatology (EULAR 2016) 6/8/2016
CoLucid Pharma (CLCD) Completes Enrollment for SAMURAI Phase III Study Evaluating Oral Lasmiditan 6/8/2016
Pfizer (PFE)'s Xeljanz Successful in Second Phase III Psoriatic Arthritis Study 6/7/2016
ASCO2016: Array BioPharma (ARRY) Presents Full Results From Phase 3 NEMO Study 6/7/2016
ImmunoCellular Therapeutics, Ltd (IMUC) Treats First Patient In ICT-107 Phase 3 Registrational Trial In Newly Diagnosed Glioblastoma 6/7/2016
Can-Fite BioPharma (CFBI) Submits Psoriasis Phase III Protocol And Registration Plan To European Medicines Agency For Piclidenoson (CF101) 6/7/2016
PARI Pharma's Investigational Closed eFlow Nebulizer System Used In Two Successful Phase 3 Clinical Studies Evaluating Sunovion Pharmaceuticals Inc.'s SUN-101 (Glycopyrrolate) In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 6/7/2016
ASCO2016: Amgen (AMGN) Release: New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis (Carfilzomib)-Based Regimen 6/7/2016
Cytori Therapeutics (CYTX) Announces Enrollment Completion In U.S. Phase III Scleroderma Trial 6/7/2016
ASCO2016: AEterna Zentaris (AEZS) Reconfirms Commitment To LHRH-Receptor Targeting Zoptrex During 2016 ASCO Annual Meeting 6/7/2016
ASCO2016: Novartis Pharmaceuticals Corporation (NVS) Combination Therapy Tafinlar + Mekinist Demonstrates Overall Survival Benefit At Three-Year Follow-Up In Patients With Advanced Melanoma 6/7/2016
Regeneron (REGN) and Sanofi (SNY)'s Dermatitis Drug Meets Goals in Late-Stage Study 6/6/2016
Ocular Therapeutix (OCUL)'s Pink Eye Treatment Dextenza Flunks Phase III Test 6/6/2016
ASCO2016: Exelixis (EXEL) And Its Partner Ipsen (IPN.PA) Announce Positive Overall Survival Results From Subgroup Analyses Of Phase III Trial Of CABOMETYX (Cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting 6/6/2016
Highland Therapeutics Announces Positive Data From Second Pivotal ADHD Trial For HLD-200 6/6/2016
Genentech (RHHBY)'s Arthritis Med Actemra Successful In Late-Stage Study in Rare Artery Inflammation 6/6/2016
Ipsen (IPN.PA) Release: Endocrine Practice Publishes ELECT Phase III Trial Results In Adults With Carcinoid Syndrome 6/6/2016
ASCO2016: Incyte (INCY) Release: Five-Year Results From Phase III Study Of Jakafi (Ruxolitinib) Show Sustained Overall Survival Benefit In Patients With Myelofibrosis (MF) 6/6/2016
ASCO2016: Ariad (ARIA)'s Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate And 12.9-Month Median Progression-Free Survival In ALTA Study 6/6/2016
ASCO2016: Mylan (MYL)-BioCon (BIOCON.NS)'s Biosimilar Cancer Drug Comparable to Roche (RHHBY)'s Herceptin 6/6/2016
Frontier Biotech's Long-Acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results Of A Phase 3 Trial 6/6/2016
ASCO2016: Celator Pharma (CPXX) Presented Phase 3 Trial Results In Patients With High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS (CPX-351) Significantly Improved Overall Survival 6/6/2016
ASCO2016: SELLAS Life Sciences Group Announces Exciting Results For Galinpepimut-S, The Company's WT1 Vaccine, In Patients With Acute Myeloid Leukemia (AML) And Malignant Pleural Mesothelioma (MPM), As Presented At The 2016 ASCO Annual Meeting 6/6/2016
ASCO2016: AbbVie (ABBV) Builds Upon Robust Body Of IMBRUVICA (Ibrutinib) Data With Phase 3 Longer-Term Studies In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Presented At The American Society Of Clinical Oncology (ASCO) Annual Meeting 6/6/2016
Merck & Co. (MRK) Partners With Array BioPharma (ARRY) And Pierre Fabre To Initiate BRAF-Mutant CRC Phase III Trial 6/6/2016
ASCO2016: OBI Pharma (SHPG) Presents Data For Novel Investigational OBI-822/OBI-821 In Patients With Metastatic Breast Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting 6/6/2016
ASCO2016: Janssen R&D Release: Daratumumab (DARZALEX) Combination Therapy Significantly Extended Progression-Free Survival In Previously Treated Patients With Multiple Myeloma 6/6/2016
Array BioPharma (ARRY), Pierre Fabre And Merck KGaA (MKGAF.PK), Darmstadt, Germany Announce Phase 3 BEACON CRC Trial 6/6/2016
Janssen Expands Body Of Evidence For INVOKANA (Canagliflozin) With 18 New Data Presentations At American Diabetes Association's 76th Scientific Sessions 6/6/2016
CVRx, Inc. Announces That The First Two Patients Were Treated In The Phase III Pivotal Trial Evaluating BAROSTIM THERAPY For The Treatment Of Heart Failure 6/6/2016
Long-Term Data From Two Trials Evaluating The Opdivo (Nivolumab) And Yervoy (Ipilimumab) Regimen In Advanced Melanoma Continues To Validate Bristol-Myers Squibb (BMY)’s Immuno-Oncology Combination Approach 6/6/2016
ASCO2016: IntegraGen, Inc. Presents Positive Data At 2016 ASCO Meeting On The Role Of Microrna Biomarker miR-31-3p In Patients With Metastatic Colorectal Cancer Enrolled In FIRE-3 Clinical Trial 6/6/2016
ASCO2016: AstraZeneca PLC (AZN) LYNPARZA (Olaparib): Latest Data Suggest Potential Overall Survival Advantage In Patients With Platinum Sensitive Ovarian Cancer 6/6/2016
Novo Nordisk A/S (NVO) To Present 53 Abstracts At 76th Annual American Diabetes Association Scientific Sessions In New Orleans, LA 6/6/2016
Axovant (AXON) Announces 2015 Fiscal Year-End Financial Results And Corporate Updates 6/6/2016
ASCO2016: Janssen Pharmaceutical Release: Daratumumab (DARZALEX) Combination Therapy Significantly Extended Progression-Free Survival In Previously Treated Patients With Multiple Myeloma 6/6/2016
Polaris Group Reports Phase III Study Results Of ADI-PEG 20 Plus Best Supportive Care In Advanced Hepatocellular Carcinoma 6/6/2016
ASCO2016: Celgene (CELG) Pooled Data From Meta-Analysis Suggest Significant Overall Survival Benefit Of Investigational REVLIMID Maintenance Following Autologous Stem Cell Transplant In Multiple Myeloma 6/6/2016
ASCO2016: AbbVie (ABBV) Builds Upon Robust Body Of IMBRUVICA (Ibrutinib) Data With Phase 3 Longer-Term Studies In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Presented At The American Society Of Clinical Oncology (ASCO) Annual Meeting 6/6/2016
Alexion (ALXN) Announces Topline Results From Phase III REGAIN Study Of Eculizumab (Soliris®) In Patients With Refractory Generalized Myasthenia Gravis (gMG) 6/6/2016
Phase III Study Shows Genentech (RHHBY)’s Actemra (Tocilizumab) Maintained Steroid-Free Remission In People With Giant Cell Arteritis (GCA) 6/6/2016
Bayer (BAY) And Orion Corporation Expand Clinical Development Program For BAY-1841788 (ODM-201) In Prostate Cancer 6/3/2016
Nektar Therapeutics (NKTR)' President And CEO, Howard W. Robin, To Present At The Jefferies 2016 Global Healthcare Conference In New York City 6/3/2016
Dermira (DERM) Jumps as Excessive Armpit Sweating Drug Succeeds in Late-Stage Studies 6/2/2016
Peregrine (PPHM) Nixes Planned Trials for Bavituximab, But Hints at a Future Trial with AstraZeneca PLC (AZN)’s Durvalumab 6/2/2016
Astellas (ALPMY) And Medivation (MDVN) Initiate Phase III Trial Of Enzalutamide In Patients With Triple-Negative Breast Cancer 6/2/2016
Genmab A/S (GEN.CO) Announces Phase III Studies Of Ofatumumab In Relapsing Multiple Sclerosis 6/2/2016
BIO2016: ContraVir To Present At 2016 Biotechnology Innovation Organization International Convention 6/2/2016
BIO2016: Resverlogix (RVX.TO) Announces Lead Drug Apabetalone Publication And Presentation At BIO International 2016 6/2/2016
Achaogen (AKAO) Reaches 50 Percent Patient Enrollment In Phase 3 EPIC Registration Trial Of Plazomicin 6/2/2016
AbbVie (ABBV)'s Research And Commitment To Helping People Living With Rheumatologic Diseases Highlighted At The Annual European Congress Of Rheumatology (EULAR 2016) 6/2/2016



//-->